GLP-1 for Low Blood Sugar
What You Need to Know Before You Apply
What is the purpose of this trial?
Low blood sugar can negatively affect how blood vessels function, and this can lead to an increase in the risk for heart attacks, strokes and other problems related to the stiffening and blockage of blood vessels. The purpose of this study is to learn if and how glucagon-like peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the effects that low blood sugar levels have on blood vessels.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
Is GLP-1 safe for humans?
GLP-1 receptor agonists are generally considered safe with a low risk of causing low blood sugar (hypoglycemia). The most common side effect is nausea, which usually happens at the start of treatment and goes away in 20-60% of people. There are also some concerns about possible effects on the thyroid gland and a controversial link to pancreatitis and cancer.12345
How is the drug GLP-1 unique for treating low blood sugar?
GLP-1 is unique because it acts as an incretin hormone, enhancing insulin response only when blood sugar levels are high, which helps prevent low blood sugar episodes. Unlike other treatments, GLP-1 also slows stomach emptying and reduces appetite, offering additional benefits for managing blood sugar levels.678910
What data supports the effectiveness of the drug GLP-1 for low blood sugar?
Who Is on the Research Team?
Stephen N. Davis, MBBS
Principal Investigator
University of Maryland, Baltimore
Are You a Good Fit for This Trial?
This trial is for adults aged 30-60 with Type 2 Diabetes who have a body mass index over 25 and controlled blood sugar levels (HbA1c between 6-10%). It's also open to healthy individuals in the same age range. People with significant diabetic complications like retinopathy or neuropathy can't participate.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive GLP-1 or saline infusion during the experimental period
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Glucagon-Like Peptide-1 (GLP-1)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Maryland, Baltimore
Lead Sponsor